JP2010530892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530892A5 JP2010530892A5 JP2010513439A JP2010513439A JP2010530892A5 JP 2010530892 A5 JP2010530892 A5 JP 2010530892A5 JP 2010513439 A JP2010513439 A JP 2010513439A JP 2010513439 A JP2010513439 A JP 2010513439A JP 2010530892 A5 JP2010530892 A5 JP 2010530892A5
- Authority
- JP
- Japan
- Prior art keywords
- compressed tablet
- total weight
- tablet
- ritonavir
- intragranular lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007891 compressed tablet Substances 0.000 claims 20
- 239000000314 lubricant Substances 0.000 claims 8
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 5
- 229960003796 Atazanavir sulfate Drugs 0.000 claims 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 5
- DQSGVVGOPRWTKI-QVFAWCHISA-N atazanavir sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 DQSGVVGOPRWTKI-QVFAWCHISA-N 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 5
- 229960000311 ritonavir Drugs 0.000 claims 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 238000005550 wet granulation Methods 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N Glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 208000005721 HIV Infections Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
Claims (13)
- リトナビル、並びに硫酸アタザナビルおよび顆粒内滑沢剤を含有する顆粒を含む圧縮錠剤であって、前記顆粒が内部領域および外部表面を有し、顆粒内滑沢剤の少なくとも一部が顆粒の内部領域に存在する圧縮錠剤。
- 圧縮錠剤の総重量に基づき、顆粒内滑沢剤を約０.１〜１０％含む、請求項１の圧縮錠剤。
- 圧縮錠剤の総重量に基づき、顆粒内滑沢剤を約０.５〜８％含む、請求項１の圧縮錠剤。
- 顆粒内滑沢剤が、ステアリン酸マグネシウム、ステアリン酸亜鉛、ステアリン酸カルシウム、ステアリン酸、パルミチン酸、フマル酸ステアリルナトリウム、安息香酸ナトリウム、ラウリル硫酸ナトリウム、モノステアリン酸グリセリン、パルミトステアリン酸グリセリン、硬化ヒマシ油、硬化植物油、鉱油、カルナウバロウ、ポリエチレングリコールおよびそれらの混合物からなる群より選択される、請求項１の圧縮錠剤。
- 圧縮錠剤の総重量に基づき、さらに崩壊剤を約１〜２０％含む、請求項１の圧縮錠剤。
- 圧縮錠剤の総重量に基づき、さらに結合剤を約０.１〜１０％含む、請求項１の圧縮錠剤。
- 圧縮錠剤の総重量に基づき、さらに賦形剤を約５〜９０％含む、請求項１の圧縮錠剤。
- 圧縮錠剤の総重量に基づき、さらに顆粒外滑沢剤を約０.１〜３％含む、請求項１の圧縮錠剤。
- 硫酸アタザナビルが１つの層中にあって、リトナビルが別の層中にあることを特徴とする多層錠剤の形態である、請求項１の圧縮錠剤。
- 硫酸アタザナビルおよびリトナビルが同一の層中にあることを特徴とする一体型（monolith）錠剤の形態である、請求項１の圧縮錠剤。
- リトナビル、硫酸アタザナビルおよび顆粒内滑沢剤を顆粒内で混合することを特徴とする湿式造粒法によって製造される、請求項１の圧縮錠剤。
- 硫酸アタザナビルおよび顆粒内滑沢剤を顆粒内で混合し、リトナビルを顆粒外で加えることを特徴とする湿式造粒法によって製造される、請求項１の圧縮錠剤。
- 請求項１の圧縮錠剤を含むＨＩＶ感染治療剤。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94569407P | 2007-06-22 | 2007-06-22 | |
| PCT/US2008/067633 WO2009002829A2 (en) | 2007-06-22 | 2008-06-20 | Tableted compositions containing atazanavir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530892A JP2010530892A (ja) | 2010-09-16 |
| JP2010530892A5 true JP2010530892A5 (ja) | 2011-07-28 |
Family
ID=39645403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513439A Pending JP2010530892A (ja) | 2007-06-22 | 2008-06-20 | アタザナビルを含む錠剤組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20100183716A1 (ja) |
| EP (1) | EP2178513B1 (ja) |
| JP (1) | JP2010530892A (ja) |
| KR (1) | KR20100033377A (ja) |
| CN (1) | CN101795674A (ja) |
| AT (1) | ATE503467T1 (ja) |
| AU (1) | AU2008268537B2 (ja) |
| CY (1) | CY1111957T1 (ja) |
| DE (1) | DE602008005896D1 (ja) |
| DK (1) | DK2178513T3 (ja) |
| ES (1) | ES2361796T3 (ja) |
| HR (1) | HRP20110294T1 (ja) |
| MX (1) | MX2009013461A (ja) |
| PL (1) | PL2178513T3 (ja) |
| PT (1) | PT2178513E (ja) |
| SI (1) | SI2178513T1 (ja) |
| WO (1) | WO2009002829A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009013499A (es) * | 2007-06-22 | 2010-01-18 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
| CA2703918C (en) * | 2007-10-29 | 2016-10-18 | Cipla Limited | Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations |
| EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US10071059B2 (en) * | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| JP6158702B2 (ja) | 2010-04-09 | 2017-07-05 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | ｐＨの影響を改善したアタザナビル硫酸塩製剤 |
| CN104884063A (zh) | 2012-10-23 | 2015-09-02 | 西普拉有限公司 | 抗逆转录病毒药物组合物 |
| WO2015028875A2 (en) * | 2013-08-29 | 2015-03-05 | Teva Pharmaceuticals Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| CN104784133A (zh) * | 2014-01-19 | 2015-07-22 | 广东东阳光药业有限公司 | 一种齐多夫定的片剂及其制备方法 |
| KR101669240B1 (ko) * | 2015-03-12 | 2016-10-25 | 아주대학교산학협력단 | 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| GB201800249D0 (en) * | 2018-01-08 | 2018-02-21 | Univ Of Sussex | Pickering emulsions |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940998A (en) * | 1953-10-15 | 1960-06-14 | Ajinomoto Kk | Process for resolution of racemic glutamic acid and salts thereof |
| GB919491A (en) * | 1958-12-23 | 1963-02-27 | Ici Ltd | Pharmaceutical compositions |
| US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
| US3980637A (en) * | 1975-03-17 | 1976-09-14 | Bristol-Myers Company | Production of amoxicillin |
| US4556654A (en) * | 1983-06-28 | 1985-12-03 | Warner-Lambert Company | Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones |
| DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| US5753652A (en) * | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
| CA2103932A1 (en) * | 1992-11-05 | 1994-05-06 | Ramesh N. Patel | Stereoselective reduction of ketones |
| US5461067A (en) * | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5428048A (en) * | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| JP3529904B2 (ja) * | 1995-06-19 | 2004-05-24 | 鐘淵化学工業株式会社 | 光学活性１−ハロ−３−アミノ−４−フェニル−２−ブタノール誘導体の製造法 |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| CA2190570C (en) * | 1995-11-17 | 2005-05-03 | Yutaka Honda | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| AU3075400A (en) * | 1999-01-21 | 2000-08-07 | Kaneka Corporation | Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives |
| EP1661893A3 (en) * | 1999-01-29 | 2006-06-07 | Kaneka Corporation | Process for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives |
| EP1165521A4 (en) * | 1999-03-22 | 2002-05-22 | Bristol Myers Squibb Co | FUSED COMPOUNDS OF PYRIDOPYRIDAZINE CGMP PHOSPHODIESTERASE INHIBITORS |
| US6605732B1 (en) * | 1999-05-03 | 2003-08-12 | Aerojet Fine Chemicals Llc | Clean, high-yield preparation of S,S and R,S amino acid isosteres |
| KR100708221B1 (ko) * | 1999-08-31 | 2007-04-17 | 아지노모토 가부시키가이샤 | 에폭사이드 결정의 제조방법 |
| US6399393B1 (en) * | 1999-09-21 | 2002-06-04 | The United States Of America As Represented By The Department Of Energy | Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| YU34501A (sh) * | 2000-05-26 | 2003-10-31 | Pfizer Products Inc. | Postupak reaktivne kristalizacije radi povećanja veličine čestica |
| AU2001280698B2 (en) * | 2000-08-16 | 2005-08-25 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Stereoselective reduction of substituted oxo-butanes |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| KR20020046948A (ko) * | 2000-12-12 | 2002-06-21 | 에가시라 구니오 | 에폭사이드 결정의 제조방법 |
| RU2316341C2 (ru) * | 2001-08-31 | 2008-02-10 | Бристол-Маерс Сквибб Компани | Применение атазанавира в терапии вич-инфекции |
| KR100933625B1 (ko) * | 2001-09-04 | 2009-12-24 | 다우 글로벌 테크놀로지스 인크. | 수성 에어 포움, 이를 사용한 고체 입자의 응집방법 및 피복방법 |
| US7384734B2 (en) * | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| FR2855756B1 (fr) * | 2003-06-06 | 2005-08-26 | Ethypharm Sa | Comprime orodispersible multicouche |
| US20050148523A1 (en) * | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
| TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
| US7582468B2 (en) * | 2005-05-25 | 2009-09-01 | Bristol-Myers Squibb Company | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
-
2008
- 2008-06-20 AT AT08771569T patent/ATE503467T1/de active
- 2008-06-20 PL PL08771569T patent/PL2178513T3/pl unknown
- 2008-06-20 SI SI200830227T patent/SI2178513T1/sl unknown
- 2008-06-20 WO PCT/US2008/067633 patent/WO2009002829A2/en active Application Filing
- 2008-06-20 ES ES08771569T patent/ES2361796T3/es active Active
- 2008-06-20 JP JP2010513439A patent/JP2010530892A/ja active Pending
- 2008-06-20 AU AU2008268537A patent/AU2008268537B2/en not_active Ceased
- 2008-06-20 EP EP08771569A patent/EP2178513B1/en active Active
- 2008-06-20 PT PT08771569T patent/PT2178513E/pt unknown
- 2008-06-20 KR KR1020097026604A patent/KR20100033377A/ko not_active Application Discontinuation
- 2008-06-20 MX MX2009013461A patent/MX2009013461A/es active IP Right Grant
- 2008-06-20 CN CN200880103484A patent/CN101795674A/zh active Pending
- 2008-06-20 DK DK08771569.4T patent/DK2178513T3/da active
- 2008-06-20 US US12/664,802 patent/US20100183716A1/en not_active Abandoned
- 2008-06-20 DE DE602008005896T patent/DE602008005896D1/de active Active
-
2011
- 2011-04-21 HR HR20110294T patent/HRP20110294T1/hr unknown
- 2011-06-28 CY CY20111100620T patent/CY1111957T1/el unknown
-
2014
- 2014-07-02 US US14/322,478 patent/US20150320731A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530889A5 (ja) | ||
| JP2010530892A5 (ja) | ||
| HRP20110294T1 (hr) | Smjese u obliku tablete koje sadržavaju atazanavir | |
| UY27995A1 (es) | Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación | |
| JP2007523210A5 (ja) | ||
| HRP20140146T1 (hr) | Smjese koje sadrže atazanavir oblikovane u tablete | |
| JP2012197280A5 (ja) | ||
| EA023807B1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
| JP2010518028A5 (ja) | ||
| JP2010530890A5 (ja) | ||
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| JP2017525712A5 (ja) | ||
| JP2008534522A5 (ja) | ||
| CO6440564A2 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| US20090317465A1 (en) | Composition and method of preparation of release systems for constant (zero-order) release of active agents | |
| JP2013231087A5 (ja) | ||
| JP2010083886A (ja) | 経口投与用粒子状医薬組成物 | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
| JP2011525501A5 (ja) | ||
| SI2729130T1 (en) | Combined formulations of darunavir | |
| WO2010020856A3 (en) | Rate modulated delivery of drugs from a composite delivery system | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| HRP20190550T1 (hr) | Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva | |
| HRP20151347T1 (hr) | Nova kombinacija |